This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/14/2025
Operator
I now turn the call over to Justin Shakma, Chief Business Officer.
Operator
Please proceed.
Justin Shakma
Chief Business Officer
Good morning, and thank you for joining our first quarter 2025 earnings conference call. This morning, we issued a press release detailing our financial results and commercial highlights, which is available in the investor and media section of our website at ars-pharma.com. With me on the call are Richard Lowenthal, our co-founder, president, and CEO, who will review recent corporate updates and achievements. Eric Peraz, our chief commercial officer, who will cover our commercial activities and progress. And Kathy Scott, our CFO, who will provide a summary of our financial results and cash position. Before we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Rich.
You're reading a preview of the SPRY Q1 2025 earnings call.
Free account.
Disclaimer